ABSTRACT: Backgro und: Dyskinesias are a disabling motor complication that arises with prolonged L-dopa treatment. Studies using D1 receptor drugs and genetically modified mice suggest that medium spiny neurons expressing D1 receptors play a primary role in L-dopa-induced dyskinesias. However, the specific role of these neurons in dyskinesias is not fully understood. Methods: We used optogenetics, which allows for precise modulation of select neurons in vivo, to investigate whether striatal D1-expressing medium spiny neuron activity regulates abnormal involuntary movements or dyskinesia in parkinsonian mice. D1-cre mice unilaterally lesioned with 6-hydroxydopamine received striatal injections of cre-dependent channelrhodopsin2 virus or control virus. After stable virus expression, the effect of optical stimulation on dyskinesia was tested in L-dopana€ ıve and L-dopa-primed mice. Results: Single-pulse and burst-optical stimulation of D1-expressing medium spiny neurons induced dyskinesias in L-dopa-na€ ıve channelrhodopsin2 mice. In stably dyskinetic mice, L-dopa injection induced dyskinesia to a similar or somewhat greater extent than optical stimulation. Combined L-dopa administration and stimulation resulted in an additive increase in dyskinesias, indicating that other mechanisms also contribute. Molecular studies indicate that changes in extracellular signalregulated kinase phosphorylation in D1-expressing medium spiny neurons are involved. Optical stimulation did not ameliorate parkinsonism in L-dopa-na€ ıve mice. However, it improved parkinsonism in L-dopa-primed mice to a similar extent as L-dopa administration. None of the stimulation paradigms enhanced dyskinesia or modified parkinsonism in L-dopa-na€ ıve or L-dopaprimed control virus mice. C on c lus i o n: The data provide direct evidence that striatal D1-expressing medium spiny neuron stimulation is sufficient to induce dyskinesias and contributes to the regulation of motor control. V C 2017 International Parkinson and Movement Disorder Society
The striatal direct and indirect pathways play a major role in basal ganglia circuit function and motor control. [1] [2] [3] GABAergic medium spiny neurons expressing D1 receptors (D1 MSNs) are the main striatal output of the direct pathway that projects to the substantia nigra pars reticulata.
1,2,4 D1 MSN stimulation inhibits substantia nigra pars reticulata activity, thereby disinhibiting its output nuclei to promote movement. [5] [6] [7] Conversely, activation of the indirect striatopallidal pathway, which comprises GammaAminobutyric acid-ergic (GABAergic) MSNs expressing D2 receptors, reduces motor activity. 6, [8] [9] [10] The loss of this bidirectional control of motor function makes MSNs primary players in the motor impairments observed in Parkinson's disease (PD) and the dyskinesias that arise with administration of the dopamine precursor L-dopa. 1, 4, 11, 12 A role for D1 MSNs in dyskinesias is supported by preclinical evidence showing that dopamine cell loss increases D1 MSN excitability possibly by enhancing the recruitment of D1 receptors to the plasma membrane. [12] [13] [14] [15] [16] [17] [18] [19] Also, the unregulated DA release that occurs with L-dopa administration results in enhanced D1 receptor signaling and abnormal internalization and trafficking. 13, 14, 20 These alterations may further exacerbate sensitized D1 MSN-mediated transmission and lead to abnormal downstream signaling responses that contribute to L-dopa-induced dyskinesias (LIDs). 1, 3, 11 Further evidence for a role of D1 MSNs in LIDs comes from studies showing that D1 receptor agonists promote dyskinesias, whereas D1 receptor antagonists reduce them. [21] [22] [23] [24] In addition, genetically modified mice lacking D1 receptors do not develop LIDs, 25 and the inhibition of D1 MSN activity via chemical ablation or chemogenetic approaches reduces LIDs. 26, 27 D2 receptor-mediated signaling also appears to modulate LIDs, although its contribution is less clear. 1, 12, 25, [28] [29] [30] [31] This is because D2 receptor agonists produce only mild or no dyskinesias in L-dopa-na€ ıve lesioned rodents. Their administration leads to more severe dyskinesia in L-dopa-primed animals, 21, 32 and D2 receptor antagonists attenuate L-dopa-induced AIMs, 23, 33, 34 suggesting that they are involved. In addition, alterations in D2 receptor-mediated signaling have been shown to contribute to LIDs. For example, increased activity of regulator of G-protein signaling 9-2 (RGS9-2), a protein that inhibits the interaction of D2 receptors with G proteins, decreases LID severity only after D1 receptor activation. 35 The objective of the present work was to directly evaluate the role of D1 MSN activation on dyskinesia development. To approach this, we used optogenetics to precisely modulate D1 MSN activity in vivo and assess how it controls dyskinesia expression in parkinsonian D1-Cre mice. The results show that selective striatal D1 MSN activation differentially regulates dyskinesias and parkinsonism in both L-dopa-na€ ıve and L-dopa-primed mice. Altogether, the data provide direct evidence that striatal D1 MSN stimulation regulates dyskinesias and parkinsonism.
Materials and Methods

Mice
Hemizygous male mice from a bacterial artificial chromosome (BAC) transgenic mouse line expressing cyclization recombinase (Cre) under the control of the dopamine D1 receptor (EY262Gsat/Mmucd, B6.FVB(Cg) background) were obtained from the Mutant Mouse Resource and Research Center (MMRRC) at the University of California at Davis, a NIH funded strain repository, and was donated to the MMRRC by the NINDS funded Gene Expression Nervous System Atlas (GENSAT) BAC transgenic project. The male mice were crossed to wildtype C57Bl/6J female mice. Female and male mice entered the study at about 8 weeks of age, weighing 18 to 25 g. They were group housed in a temperature-and humiditycontrolled environment under a 12-hour light/dark cycle with free access to food and water.
6-Hydroxydopamine Lesion
After a 2-to 3-day acclimation period, the mice were treated as in Figure 1A . All mice were lesioned 5 30.48) . Each bar is the mean 6 standard error of the mean of 5 mice. Significantly different from D1-eYFP, *P .05, **P .01, ***P .001, using a Bonferroni multiple-comparison test. 6-OHDA, 6-hydroxydopamine; Cre, cyclization recombinase; ChR2, channelrhodopsin-2; eYFP, enhanced yellow fluorescent protein. 
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Viral Expression
At 4 weeks after 6-OHDA lesioning, mice were stereotaxically injected into the right striatum with creinducible adeno-associated virus (AAV) vector tagged with enhanced yellow fluorescent protein (eYFP) and expressing channelrhodopsin (ChR2) 
Optical Stimulation
We used optical stimulation paradigms consistent with those previously used to modulate D1 MSN activity. 6, 7 Striatal D1 MSNs were activated using a 473-nm DPSS blue laser (Shanghai Laser, Shanghai, China) with a maximum output power >120 mW. The laser was controlled by a Master-8 (A.M.P.I. Ltd., Jerusalem, Israel) and its power adjusted such that it was 1.5 mW at the fiber tip of each optical implant (measured with a PM100D optical power meter power with an S130C sensor; Thorlabs Inc., Newton, New Jersey). Optical stimulation consisted of a single pulse ranging from 5 milliseconds to 30 seconds in duration or a burst of 10 to 50 pulses (20-millisecond pulse duration) at a frequency of 10 to 20 Hz. Stimulation was delivered with a 0.5-second off stimulation period between pulses or bursts throughout the entire rating period as detailed in the Dyskinesia Ratings section.
Assessment of Motor Deficits
6-OHDA-induced motor impairment was assessed using the cylinder or forelimb-use asymmetry test. [37] [38] [39] Exploratory activity was rated by a blinded rater for 3 minutes in the absence and presence of optical stimulation with and without L-dopa. Ratings were performed immediately before and 60 minutes after Ldopa, when the drug effects are maximal. Wall exploration was expressed in terms of the percentage use of the impaired contralateral forelimb compared to the total number of forelimb contacts.
37-39
Dyskinesia Ratings
Abnormal involuntary movements (AIMs) were rated by a blinded rater at least once weekly as described. [36] [37] [38] [40] [41] [42] Each AIM subtype (oral, forelimb, and axial) was scored on a frequency scale from 0 to 4 (0 5 no dyskinesia; 1 5 occasional dyskinesia displayed for <50% of the observation time; 2 5 sustained dyskinesia displayed for >50% of the observation time; 3 5 continuous dyskinesia; 4 5 continuous dyskinesia not interruptible by external stimuli). Amplitude scores were subdivided as "A," which indicates oral AIMs without tongue protrusion, forelimb AIMs without the shoulder engaged, and axial AIMs with body twisting <608, or "B," indicating oral AIMs with tongue protrusion, forelimb AIMs with the shoulder engaged, or axial AIMs with body twisting 608. Overall scores for the frequency and amplitude of AIMs used for data analysis were calculated as 1A 5 1, 1B 5 2, 2A 5 2, 2B 5 4, 3A 5 4, 3B 5 6, 4A 5 6, 4B 5 8. This allows for scores for any 1 component (axial, oral, or forelimb) ranging from 1 to 8. Total AIM scores were calculated as the sum of all the components, with a maximum possible total score of 24 per time point.
Experiments in L-dopa-na€ ıve mice were initiated 5 weeks after virus injection. AIMs were rated every 5 minutes for 1 hour, 30 minutes in the absence of stimulation, and 30 minutes in the presence of stimulation in random order. Any 1 mouse was only subjected to 1 stimulation paradigm per week, with the different paradigms tested on a random basis.
After a total of 11 stimulation sessions, the mice were injected subcutaneously with L-dopa (3-5 mg/kg) and benserazide hydrochloride (15 mg/kg) once daily 5 days per week to induce AIMs. For all L-dopaprimed mice, AIMs were scored individually by a blinded rater every 15 minutes for 1 minute for a 2-hour period after L-dopa injection.
Tissue Preparation
The mice were killed by cervical dislocation and the brains quickly removed and bisected at the midstriatal level. The anterior portion was postfixed in 4% paraformaldehyde and cryopreserved in 10% to 30% sucrose for several days. The fixed brains were sectioned (30 lm) using a cryostat (Leica, Buffalo Grove, Illinois) for immunofluorescence. The posterior portion of the brain was quick frozen in isopentane on dry ice and stored at 2808C for autoradiography.
Immunofluorescence
Staining for dopamine-and cyclic adenosine monophosphate-regulated phosphoprotein-32 (DARPP-32) or phosphorylated extracellular regulated kinase (p-ERK) was performed on every 6th section from A1.4 to A0.2. Free-floating sections were rinsed three times in 0.3% Triton X-100 in phosphate buffered saline (PBS), and then exposed to a blocking solution consisting of 3% normal goat serum in 0.3% Triton X-100 in PBS for 1 hour. The sections were then incubated with rabbit anti-DARPP-32 (1:800, Cell Signaling Technology, Danvers, Massachusetts) or rabbit anti-phospho-ERK1/2 (1:250 dilution; Cell Signaling Technology) overnight at 48C. This was followed by incubation with a secondary antibody (goat anti-rabbit Alexa-555; dilution 1:500; Cell Signaling Technology) for 2 hours at room temperature. Sections were then rinsed in PBS, mounted onto slides with a Vectashield mounting medium (Vector laboratories, Burlingame, CA), cover slipped, and viewed under a Nikon (Melville, New York) fluorescence microscope.
To evaluate the colocalization of ChR2-eYFP with DARPP-32 or p-ERK, the images were captured at 103 and 403 magnifications to view viral expression in striatal neurons. DARPP-32/eYFP or p-ERK/eYFP double-positive cells were counted manually at 1A0.8 mm from Bregma by a blinded rater using Adobe (San Jose, California) Photoshop software merged images, as described. 38 Mean values were calculated for each animal and considered as an individual observation for statistical analyses.
Dopamine Transporter Autoradiography
125 I-RTI-121 (specific activity, 2200 Ci/mmol; GE Healthcare, Chalfont St. Giles, Buckinghamshire, United Kingdom) autoradiography was performed as described. 43 
Statistical Analyses
Statistical comparisons were performed using GraphPad Prism (GraphPad Software Co., San Diego, California). Because the behavioral data involves integrated or continuous data collected during an extended time frame, that is, the total or area under the time curve (2-hour period) of all scores, paired t tests or analysis of variance followed by a Bonferroni multiple-comparison test were used. For the molecular studies, t tests were used. A level of .05 was considered significant. Values are the mean 6 standard error of the mean of the indicated number of mice.
Results
Optical Stimulation Induces Oral AIMs in
Lesioned L-dopa-Na€ ıve Mice D1-Cre mice were first lesioned with 6-OHDA to induce nigrostriatal damage and tested for parkinsonism 2 weeks later using the forelimb asymmetry test. 6-OHDA lesioning decreased left forelimb use from 51 6 0.5% to 33 6 2.2%, as described. 37, 38 Such declines in forelimb use are consistent with the observed 91 6 13% (n 5 9) and 98 6 14% (n 5 4) loss in dopamine transporter binding in the lesioned striatum of D1-ChR2 and D1-eYFP mice, respectively, in agreement with previous studies. 37, 38, 41, 42 We next tested various stimulation paradigms to evaluate whether the optical stimulation of striatal D1 MSNs led to AIMs. Optical stimulation consisting of single-pulse durations ranging from 0.1 to 30 seconds significantly increased total AIMs in D1-ChR2 mice, with no effect of 0.005-second, single-pulse stimulation (Fig. 1B) . As previous studies showed that a 1 second optical stimulation causes D1 MSN neurons to fire at a rate of about 10 Hz, we also tested the effect of stimulation using 10 or 50 pulses delivered at 10 or 20 Hz. 6, 7 Burst stimulation increased total AIMs in D1-ChR2 mice to a similar level as the single pulses (Fig. 1B) . None of the stimulation paradigms induced AIMs in D1-eYFP mice (Fig. 1B) . Thus, enhanced D1 MSN activity induced AIMs only in the D1-ChR2 mice.
We also assessed how D1 MSN stimulation influenced the expression of AIM subtypes (axial, oral, forelimb). For the single-pulse paradigms, the D1 MSN stimulation-induced increase in AIMs was primarily a result of enhanced oral AIMs in the D1-ChR2 mice (Fig. 1C) . Likewise, burst stimulation with 50 pulses at 10 Hz increased the oral AIMs to a similar extent as single-pulse stimulation (Fig. 1D) . The increase in AIMs was observed immediately after the onset of stimulation and lasted throughout the stimulation period as shown in the time courses (Fig.  1C,D) . As expected, no effect of stimulation was observed in the D1-eYFP mice (Fig. 1C,D) .
D1 MSN Stimulation Induces a Higher Level of AIMs in L-dopa-Primed When Compared With
L-dopa-Na€ ıve Lesioned D1-Cre Mice
The data in Figure 2 show that the AIM scores for L-dopa-na€ ıve unilaterally lesioned D1-Cre mice expressing D1-ChR2 stimulated with a 1-second ( Fig.  2A) or a 10-pulse/10 Hz (Fig. 2B) stimulus delivered every 0.5 seconds. The mice were subsequently treated for 3 weeks with daily injections of L-dopa (3 mg/kg) until stably dyskinetic. Total AIMs were similar for the D1-eYFP (32 6 4.2, n55) and D1-ChR2 (24 6 3.3, n511) mice, as reported. 37 The L-dopa-primed
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mice were then optically stimulated (in the absence of an acute L-dopa dose) with a single pulse (1-second) or a burst (10 pulses at 10 Hz), and the AIMs were rated. No effect of stimulation was observed in the D1-eYFP mice. Conversely, stimulation enhanced total AIMs to a significantly greater extent in L-dopaprimed than L-dopa-na€ ıve D1-ChR2 mice ( Fig. 2A,B) . Notably, optical stimulation induced oral and forelimb AIMs in L-dopa-primed mice ( Fig. 2A,B) , whereas it primarily generated oral AIMs in L-dopa-na€ ıve mice (Fig. 1C,1D ). Such differences may arise from the fact that optical stimulation only activates D1 MSNs within the dorsolateral striatum, whereas L-dopa would have a more generalized effect.
Additive Effect of Combined D1 MSN Stimulation and L-dopa on AIMs Expression in
Lesioned L-dopa-Primed D1-Cre Mice
We next investigated the level of AIMs obtained with D1 MSN stimulation alone, L-dopa treatment alone, or the combination. In D1-eYFP mice, acute L-dopa injection induced oral and forelimb AIMs; however, optical stimulation had no effect as expected (Fig. 3A) . In contrast, both optical stimulation and Ldopa treatment induced AIMs in D1-ChR2 mice as depicted in the time courses (Fig. 3B-D) . Although AIMs were significantly higher with L-dopa treatment than with the 1-second pulse optical stimulation (Fig.  3B) , burst stimulation-induced AIMs were similar to those obtained with L-dopa administration (Fig. 3C) . Combined optical stimulation and L-dopa injection resulted in AIMs higher than either condition alone regardless of stimulation paradigm (Fig. 3B,C) .
We also examined the effect of optical stimulation in the absence and presence of 5 mg/kg L-dopa to evaluate whether the apparent additive effect of optical stimulation and L-dopa was a result of a submaximal effect of the lower 3 mg/kg L-dopa dose. A 5 mg/kg Ldopa dose induced AIMs to a level comparable to that obtained with 3 mg/ kg L-dopa for both the D1-ChR2 (24 6 5.5) and D1-eYFP (39 6 6.3) mice, indicating that maximal L-dopa-induced AIMs had been achieved with the lower L-dopa dose. Optical stimulation alone-induced AIMs were still lower than
FIG. 2. Medium spiny neuron expressing D1 receptor (D1 MSN) stimulation induces a higher level of abnormal involuntary movements (AIMs) in L-
dopa-primed when compared with L-dopa-na€ ıve lesioned D1-Cre mice. L-dopa-na€ ıve unilaterally lesioned D1-Cre mice expressing D1-ChR2 or D1-eYFP received no L-dopa; they were then stimulated and AIMs rated. The mice were subsequently treated with L-dopa (3 mg/kg) until stably dyskinetic. AIMs were next rated in the absence of L-dopa in response to a 1-second (A) or a 10 pulse/10 Hz (B) stimulus delivered every 0.5 seconds. As expected, the optical stimulation did not induce AIMs in L-dopa-na€ ıve or L-dopa-primed D1-eYFP mice (data not shown). Each bar is the mean 6 standard error of the mean of 5 mice. Significantly different from L-dopa-na€ ıve, *P .05, **P .01, using a paired Student t test. Cre, cyclization recombinase; ChR2, channelrhodopsin-2; eYFP, enhanced yellow fluorescent protein. 
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L-dopa-induced AIMs in the D1-ChR2 mice treated with 5 mg/kg L-dopa (Fig. 3D) . In addition, an additive effect of L-dopa administration and optical stimulation was also evident (Fig. 3D ). These data suggest that additional adaptive responses extending beyond enhanced D1 MSN activity contribute to the expression of L-dopa-induced dyskinesias.
D1 MSN Stimulation Improves Motor Deficits in Lesioned L-dopa-Primed Mice
Because D1 MSN activity is associated with the facilitation of movement, 6, 7 we evaluated whether direct D1 MSN stimulation improved parkinsonism in 6-OHDA lesioned mice. First, we tested the effect of D1 MSN stimulation in L-dopa-na€ ıve D1-ChR2 and D1-eYFP mice. The animals were rated for left forelimb use for 3 minutes in the absence of stimulation. They were then tested for 3 minutes in the presence of a 1-second stimulating pulse applied every 0.5 seconds throughout the rating period. Optical stimulation did not improve parkinsonism in either the D1-ChR2 or D1-eYFP L-dopa-na€ ıve mice (Fig. 4A) . The mice were subsequently treated with L-dopa (3 mg/kg) for 3 weeks until stably dyskinetic. Parkinsonism was then rated in the absence of L-dopa as well as 1 hour after its injection. L-dopa injection improved forelimb use in   FIG. 4 . Medium spiny neuron expressing D1 receptor (D1 MSN) stimulation improves parkinsonism in L-dopa-primed but not L-dopa-na€ ıve mice. A: L-dopa-na€ ıve lesioned D1-Cre mice expressing D1-ChR2 or control e-YFP were rated for forelimb use in the absence and presence of a 1-second pulse stimulation delivered every 0.5 seconds for 3 minutes. Optical stimulation did not affect parkinsonism in L-dopa-na€ ıve mice. B: The mice were subsequently treated with 3 mg/kg L-dopa 1 time daily, 5 times a weekk for 2 months, and parkinsonism was rated again in the absence and presence of L-dopa with and without stimulation. Optical stimulation significantly improved forelimb use in L-dopa-primed D1-ChR2 mice (F 1,9 5 12.42). As expected, L-dopa alone also improved motor impairment (F 1,9 5 15.87), and this effect was not enhanced by optical stimulation. Each bar is the mean 6 standard error of the mean of 5 to 11 mice. Significantly different from No stimulation (stim) condition, **P .01; significantly different from No L-dopa condition,
11
P .01, 111 P .001, using a Bonferroni multiple-comparison test. Cre, cyclization recombinase; ChR2, channelrhodopsin-2; eYFP, enhanced yellow fluorescent protein.
the D1-eYFP mice (46 6 3.4% forelimb use vs 27 6 2.7% before L-dopa; Fig. 4B ). As expected, optical stimulation did not affect parkinsonism in the D1-eYFP mice (Fig. 4B) . In contrast, optical stimulation improved left forelimb use in ChR2-expressing mice (36 6 3.8% forelimb use) when compared with the baseline condition (26 6 3.5% forelimb use) in the absence of L-dopa (Fig. 4B) . L-dopa administration increased forelimb use (43 6 1.3% forelimb use) to a similar extent as optical stimulation in L-dopa-primed mice (Fig. 4B) . Combined optical stimulation and Ldopa treatment did not further improve parkinsonism (46 6 1.3% forelimb use) when compared with either treatment alone in D1-ChR2 mice (Fig. 4B) . These results suggest that L-dopa priming is required for optical stimulation to ameliorate parkinsonism.
Viral Expression in Striatal MSNs of Lesioned D1-Cre Mice
To verify the presence of ChR2 in striatal D1 MSNs, fixed striatal slices containing ChR2-eYFP positive neurons were processed for DARPP-32 immunoreactivity. A representative image (Fig. 5A) shows the expression of ChR2 in the dorsal striatum at the level of the injection site (A0.8), with expression extending from A1.4 to A.0.2. Co-immunostaining of DARPP-32 and eYFP indicated clear colocalization throughout the striatum, with the images in Figure 5B showing the data around the site of injection (A0.8). The spread of D1-ChR2 and D1-eYFP was similar from levels A1.4 to A0.2. Striatal eYFP1 cell counts showed that variability in viral expression averaged 23.5% among mice (n 5 11).
Increased p-ERK Expression in D1 MSNs of Lesioned D1-ChR2 but not D1-eYFP Mice
Increased phosphorylation of ERK 1/2 in D1 MSNs has been associated with LIDs. 4, 24, [44] [45] [46] Therefore, we determined if alterations in p-ERK expression are associated with the optical stimulation-induced changes in AIMs expression observed in D1-ChR2 mice. A significant increase in the number of p-ERK 1 striatal D1 MSNs was observed in D1-ChR2 but not D1-eYFP mice (Fig. 5C-E) . No significant differences in p-ERK 1 non-D1 neurons were observed between the D1-ChR2 and D1-eYFP mice (Fig. 5E) . Thus, increased p-ERK may play a role in the changes in AIMs observed with optical D1 MSN stimulation.
Discussion
The present studies are the first to show that selective activation of D1 MSNs in the dorsal striatum induces AIMs in L-dopa-na€ ıve D1-Cre mice expressing ChR2. Our studies also show that L-dopa treatment further enhances the effect of D1 MSN stimulation on AIMs and that combined L-dopa administration and optical stimulation result in an additive increase in AIMs. These data strengthen the pivotal role of D1 MSNs on dyskinesias and suggest that other mechanisms, including those related to D2 and possibly 
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D3 receptor activation, may also underlie AIMs. 18, 19, 23, 31, 47, 48 We first investigated the effect of D1 MSN stimulation in L-dopa-na€ ıve lesioned animals because enhanced D1 MSN responsiveness is linked to the development of L-dopa-induced AIMs. 1, 4, 30, 46 Optical stimulation with brief 0.005-second pulses did not induce AIMs consistent with previous studies showing that it requires about 0.04 seconds of optical stimulation for D1 MSNs to significantly increase their firing rate. 7 We also tested the effect of single pulses ranging from 0.1 to 30 seconds in duration because previous work showed that the firing rate of striatal D1 MSNs is increased with these stimulus durations. 6, 7 In addition, we used burst stimulation paradigms comparable to the firing frequencies previously reported to occur in D1 MSNs neurons after single-pulse optical stimulation. 6, 7 We observed a similar increase in AIMs in Ldopa-na€ ıve mice with single pulses 0.1 seconds and burst stimulation, indicating that AIMs expression is likely a result of D1 MSN burst activity. Although previous work had shown that optical stimulation consisting of single-pulse durations of 0.1 seconds did not modify locomotor behavior in normal animals, 6 we observed a worsening of dyskinesias with this stimulation paradigm. These findings are consistent with studies in lesioned animals showing that D1 MSN excitability increases after DA depletion possibly to compensate for the loss of excitatory D1 receptor stimulation. 12, 18, 19 Overall, these data provide experimental evidence for a direct role of D1 MSN activation in the development of dyskinesias.
We next examined the effect of optical stimulation in L-dopa-primed lesioned mice. The results show that activation of D1 MSNs led to significantly higher AIMs in L-dopa-primed than in L-dopa-na€ ıve mice. Such findings are consistent with previous work showing that L-dopa treatment leads to poorly regulated fluctuations in synaptic dopamine levels in the lesioned striatum that contribute to L-dopa sensitization and the emergence of dyskinesias 1, 3, 4, 28, [49] [50] [51] In addition, Ldopa treatment impairs D1 receptor internalization and trafficking, leading to their increased recruitment at the plasma membrane of D1 MSNs. 13, 14, 20 Such altered receptor expression has been linked to the coupling of D1 receptors to Guanine nucleotide-binding protein G-alpha olfactory type (G aolf ) proteins which, in turn, increases adenylyl cyclase type 5 expression in D1 MSNs and activates the cyclic adenosine monophosphate (cAMP)/Protein Kinase A (PKA)/DARPP-32) and ERK signaling pathways. 1, 3, 4, 14, 30, 45, [51] [52] [53] These modifications likely contribute to the enhanced D1 MSN-mediated activity associated with LIDs. In fact, our studies showed enhanced p-ERK labeling only in the D1 MSNs of mice expressing D1-ChR2, indicating that activating these neurons potentiates ERK signaling in L-dopa-treated mice. Thus, the enhanced expression of optically stimulated AIMs in L-dopa-primed mice is consistent with the idea that Ldopa sensitizes D1 MSN-mediated signaling. Future work will examine the effect of D1 MSN activation on murine osteosarcoma viral oncogene homologus B (FosB) in striatal D1 MSNs because increased levels correlate with the intensity of dyskinetic symptoms in lesioned L-dopa-treated rodents. 25, 46, 54, 55 Our findings suggest that D1 MSNs are critical to AIMs development; however, other systems also appear to be involved. This possibility stems from the data showing that AIMs were higher with L-dopa treatment than with the 1-second D1 MSN stimulation condition. Because L-dopa-derived dopamine activates both D1-like and D2-like receptors, these data suggest that D2 MSNs also contribute to the expression of AIMs.
Unexpectedly, combined L-dopa administration and optical stimulation led to an additive increase in AIMs. This may be a result of interactions between the D1 direct and the D2 indirect striatal pathways that lead to changes in overlapping intracellular signaling cascades that modulate transcription factors, gene expression, and MSN plasticity to enhance L-dopa-induced AIMs. 1, 3, 4, 30, 31, 45, 52, 53 For instance, there is evidence that striatal D1 and D2 MSN function is influenced by collateral connections between these 2 neuronal populations. [56] [57] [58] [59] This synaptic connectivity is significantly downregulated with dopamine depletion, which may contribute to the altered MSN activity observed with motor abnormalities. 56 D1 MSN activation may not only contribute to dyskinesias but also modulate parkinsonism. We did not observe an effect of optical stimulation in L-dopana€ ıve mice, in contrast to recent optogenetic studies involving D1 MSN activation. 6, 7 This differential response may have arisen from variations in the lesioning protocol and/or the behavioral tests used. D1 MSN activation improved parkinsonism in L-dopaprimed animals possibly because of long-term L-dopainduced signaling changes. Lesion-induced parkinsonism may disrupt the bidirectional synaptic plasticity of D1 and D2 MSNs, leading to underactivity of the direct pathway and overactivity of the indirect pathway via long-term depression or potentiation, respectively. 2, 29, 60 In L-dopa-primed dyskinetic mice, L-dopa administration induces long-term depression in D2 MSNs and long-term potentiation in D1 MSNs. 29 Thus, chronic L-dopa treatment may modify the outcome of D1 activation by altering the functional interactions between D1 and D2 MSNs. These altered responses may explain the enhanced AIM expression and the antiparkinsonian effect of D1 MSN activation on L-dopa-primed animals as well as their increased responsiveness to burst stimulation.
